Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPFT trifluoroacetate
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Peptides
- Administration
- Subcutaneous, Intravenous
01
Overview
CPFT trifluoroacetate (also known as the kisspeptin analog C6) is a synthetic peptide developed by Assistance Publique - Hôpitaux de Paris (AP-HP) for the treatment of infertility. It acts as a potent agonist of the kisspeptin receptor (KISS1R, formerly GPR54), which is a key upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus, CPFT stimulates the pulsatile release of GnRH. This subsequently triggers the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland, promoting follicular development and ovulation. The C6 analog was specifically designed to offer improved metabolic stability and a longer half-life compared to native kisspeptin-10, making it a viable therapeutic candidate for conditions such as hypothalamic amenorrhea and hypogonadotropic hypogonadism.
- Other names
- Kisspeptin-10 analog C6Kisspeptin10 analog C6Kisspeptin 10 analog C6Kisspeptin-C6 trifluoroacetateKisspeptin-C-6 trifluoroacetateKisspeptin-C 6 trifluoroacetate
02
Targets
KISS1R (Kisspeptin receptor)
Beyond the preview
Go deeper on CPFT trifluoroacetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPFT trifluoroacetate.